Founded in 1942 by surgeon Alfred Blalock and surgical technician Vivien Thomas, the Cardiac Surgery Research Lab at The Johns Hopkins Hospital serves not only to spearhead discovery and innovation in cardiothoracic surgery, but also to train future leaders in the field. Active areas of investigation include the development of novel, nanoparticle-based therapeutics to mitigate acute lung injury, avoid neurological injury during cardiac surgery, and improve organ preservation during heart and lung transplantation. The lab is also active in a variety of clinical research projects aimed at improving outcomes for our patients. Equally important, the lab plays a critical role in training residents for impactful careers in academic cardiothoracic surgery. Medical students, residents, and fellows receive hands-on simulation experiences to hone surgical skills outside of the operating room. The lab also serves as a training ground to develop research and investigation skills as trainees learn methods of advanced statistical analysis and academic writing. Special programs for undergraduates and medical students help develop their passion for cardiac surgery and surgical research, giving unique opportunities to young talent.

The Allan Gelber Lab conducts research on the clinical epidemiology of rheumatic disorders. Our recent studies have explored topics that include the predicting factors of prevalent and incident gout; cardiovascular disease burden and risk in patients with rheumatoid arthritis; autoantibodies in both primary and secondary SjogrenÕs syndrome; and predictors of outcomes in patients with scleroderma. In addition, we have a long-standing interest in the ways in which racial differences affect disease manifestations in relation to rheumatic disorders.

The Ana-Marie Orbai Lab focuses on inflammatory arthritis. Current clinical research projects in the lab examine patient symptoms and experiences in rheumatic diseases and inflammatory arthritis. We focus on stiffness in rheumatoid arthritis and patient-reported outcomes. Previous research in the lab focused on systemic lupus erythemaous (SLE).

Ari Cedars, M.D., and his team have three primary research goals. First, the Cedars Lab is interested in patient-centered outcomes in congenital heart disease, which they investigate using a digital tracking system to record participants’ symptoms and quality of life. Second, the Cedars Lab investigates outcomes with mechanical circulatory support and transplant in congenital heart disease, with a focus on those with end-stage heart disease and a Fontan circulation. Third, the Cedars Lab is interested in the biological mechanisms underlying circulatory deterioration and end-organ dysfunction in patients with a Fontan circulation.

Research in the Alison E. Turnbull Lab focuses on patient-clinician interactions. We study decision-making processes for ICU patients and their families and focus on the long-term outcomes of ICU survivors. Additional research examines ways to improve end-of-life care for patients.

The Saleh Alqahtani Lab has conducted clinical research on the management of fatty liver disease and viral hepatitis, including novel therapies. We’ve also been involved in various clinical trials related to liver cirrhosis, liver cancer and outcomes of liver transplant patients.

Our lab evaluates new medications and/or techniques for the treatment of drug use disorder by conducting human laboratory studies to sensitively assess drug effects, and randomized controlled trial evaluations of medications for clinical treatment outcomes. We also focus on the development of outcome measures that are sensitive and clinically relevant.